Skip to main content
. 2023 Aug 1;26(8):434–438. doi: 10.34172/aim.2023.66

Table 3. Prognosis of Undiagnosed Patients Receiving Empiric Therapy or Observational Follow-up .

Prognosis Empiric Therapy*
(n=21)
Observational Follow-up
(n=20)
P
Clinical symptom 0.488
Improved 21 (100.0%) 19 (95.0%)
Unchanged 0 (0.0%) 1 (5.0%)
Endoscopic finding 0.258
Improved 8 (38.1%) 9 (45.0%)
Unchanged 3 (14.3%) 0 (0.0%)
Aggravating 0 (0.0%) 1 (5.0%)
Unknown 10 (47.6%) 10 (50.0%)

*Empiric therapy includes 5-ASA, probiotics, and 5-ASA plus probiotics.